222 related articles for article (PubMed ID: 19651631)
1. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
Obszynska JA; Atherfold PA; Nanji M; Glancy D; Santander S; Graham TA; Otto WR; West K; Harrison RF; Jankowski JA
Gut; 2010 Feb; 59(2):156-63. PubMed ID: 19651631
[TBL] [Abstract][Full Text] [Related]
2. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
3. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.
Haigh CR; Attwood SE; Thompson DG; Jankowski JA; Kirton CM; Pritchard DM; Varro A; Dimaline R
Gastroenterology; 2003 Mar; 124(3):615-25. PubMed ID: 12612900
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
5. Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus.
Lee Y; Urbanska AM; Hayakawa Y; Wang H; Au AS; Luna AM; Chang W; Jin G; Bhagat G; Abrams JA; Friedman RA; Varro A; Wang KK; Boyce M; Rustgi AK; Sepulveda AR; Quante M; Wang TC
Oncotarget; 2017 Jan; 8(1):203-214. PubMed ID: 27448962
[TBL] [Abstract][Full Text] [Related]
6. PPI-induced hypergastrinaemia and Barrett's mucosa: the fog thickens.
Waldum HL; Hauso Ø; Sandvik AK
Gut; 2010 Aug; 59(8):1157-8; authr reply 1158. PubMed ID: 20639256
[No Abstract] [Full Text] [Related]
7. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
8. Randomized Controlled Trial of the Gastrin/CCK
Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.
Jankowski JAZ; de Caestecker J; Love SB; Reilly G; Watson P; Sanders S; Ang Y; Morris D; Bhandari P; Brooks C; Attwood S; Harrison R; Barr H; Moayyedi P;
Lancet; 2018 Aug; 392(10145):400-408. PubMed ID: 30057104
[TBL] [Abstract][Full Text] [Related]
10. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
11. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
12. Transepithelial leak in Barrett's esophagus patients: the role of proton pump inhibitors.
Farrell C; Morgan M; Tully O; Wolov K; Kearney K; Ngo B; Mercogliano G; Thornton JJ; Valenzano MC; Mullin JM
World J Gastroenterol; 2012 Jun; 18(22):2793-7. PubMed ID: 22719187
[TBL] [Abstract][Full Text] [Related]
13. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
14. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
15. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.
Wang JS; Varro A; Lightdale CJ; Lertkowit N; Slack KN; Fingerhood ML; Tsai WY; Wang TC; Abrams JA
Am J Gastroenterol; 2010 May; 105(5):1039-45. PubMed ID: 19904251
[TBL] [Abstract][Full Text] [Related]
17. Potent gastric acid inhibition in the management of Barrett's oesophagus.
Lanas A
Drugs; 2005; 65 Suppl 1():75-82. PubMed ID: 16335861
[TBL] [Abstract][Full Text] [Related]
18. Barrett's oesophagus: the new endoscopic modalities have a future.
Deviere J
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006
[TBL] [Abstract][Full Text] [Related]
19. Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing.
Kuipers EJ
Gut; 2010 Feb; 59(2):148-9. PubMed ID: 20176635
[No Abstract] [Full Text] [Related]
20. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
